Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Obinutuzumab (Gazyva) for Follicular Lymphoma (previously untreated)
(Notification to Implement Issued as of November 16, 2018)

Apalutamide (Erleada) for Castrate Resistant Prostate Cancer 
(Notification to Implement Issued as of November 16, 2018)

Nivolumab (Opdivo) in combination with Ipilimumab (Yervoy) for Renal Cell Carcinoma
(Notification to Implement Issued as of November 16, 2018)

Pembrolizumab (Keytruda) for Melanoma Adjuvant Treatment
(Pending Submission as of November 9, 2018)

Brigatinib (Alunbrig) for Non-Small Cell Lung Cancer
(Pending Submission as of November 7, 2018)

Abemaciclib (Brand Name: TBD) for Metastatic Breast Cancer
(Pending Submission as of November 5, 2018)

Ixazomib (Ninlaro) for Multiple Myeloma (2nd-beyond)
(Pending Submission as of November 2, 2018)

 

Find a Drug Review